Skip to main content
Clinical Trials/NCT04498091
NCT04498091
Unknown
N/A

EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

Centre Hospitalier Universitaire Dijon1 site in 1 country35 target enrollmentMarch 15, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Acute Myocardial Infarction
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
35
Locations
1
Primary Endpoint
Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
Last Updated
5 years ago

Overview

Brief Summary

The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.

Registry
clinicaltrials.gov
Start Date
March 15, 2020
End Date
July 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without pneumonia
  • patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without COVID 19

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection

Time Frame: Through study completion, an average of 1 year

Study Sites (1)

Loading locations...

Similar Trials